Molecular Glue Degrader
Neuroinflammation
Key Facts
About Ternary Therapeutics
Ternary Therapeutics is an early-stage, privately-held biotech pioneering a computational platform for the rational design of molecular glues. The company combines advanced machine learning and molecular dynamics simulations to identify and optimize compounds that induce novel protein-protein interactions, primarily for targeted protein degradation and activation. Backed by European venture capital, TernaryTx is advancing a pre-clinical pipeline focused on inflammatory and fibrotic diseases while leveraging the expertise of a team with a strong track record in AI-driven drug discovery.
View full company profileAbout Ternary Therapeutics
Ternary Therapeutics is an early-stage, privately-held biotech pioneering a computational platform for the rational design of molecular glues. The company combines advanced machine learning and molecular dynamics simulations to identify and optimize compounds that induce novel protein-protein interactions, primarily for targeted protein degradation and activation. Backed by European venture capital, TernaryTx is advancing a pre-clinical pipeline focused on inflammatory and fibrotic diseases while leveraging the expertise of a team with a strong track record in AI-driven drug discovery.
View full company profileTherapeutic Areas
Other Neuroinflammation Drugs
| Drug | Company | Phase |
|---|---|---|
| Lumipulse® G sTREM2 Assay | fujirebio-diagnostics | Research Use Only |